Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Mauna Kea Technologies Announces Cellvizio® Placement at Florida Hospital Center for Interventional Endoscopy

Mauna Kea Technologies
Posted on: 31 Aug 16

PR Newswire

PARIS, August 30, 2016

PARIS, August 30, 2016 /PRNewswire/ --

Internationally recognized Center for Interventional Endoscopy is highest volume interventional endoscopy unit in the U.S.  

Cellvizio to be featured at CIE's 4 th  Annual Orlando Live EUS symposium September 7-9
  

Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the placement of a Cellvizio System at the Florida Hospital Center for Interventional Endoscopy (CIE) in Orlando, Florida. The CIE is an internationally recognized leader in therapeutic endoscopy and minimally invasive surgery for patients with complex digestive diseases, providing a significant opportunity to drive increased awareness of the Cellvizio platform in the clinical and research communities.

Shyam Varadarajulu, M.D., Medical Director at CIE, said, "The Florida Hospital Center for Interventional Endoscopy (CIE) has adopted Cellvizio so that patients can be evaluated using cutting-edge diagnostic technology. Cellvizio will help expand CIE's advanced imaging portfolio and facilitate better management of patients. A major mission of CIE is to conduct high quality clinical trials and we hope that Cellvizio will be instrumental in providing answers to diagnostic dilemma in the evaluation of pancreatic cysts and indeterminate biliary strictures."

In 2015, CIE was the leading center in Florida by volume, performing 6,216 complex endoscopic procedures. Their endoscopic ultrasound (EUS) unit was the largest volume center in the U.S. for the second consecutive year, performing 2,753 procedures. This included 831 fine needle aspiration (FNA) procedures, a procedure that may often be improved with real-time tissue evaluation provided by Cellvizio guided needle-based Confocal Laser Endomicroscopy (nCLE). In addition, CIE faculty published 55 peer-reviewed manuscripts in 2015, including 24 abstracts accepted for presentation at Digestive Disease Week (DDW) 2016. The Cellvizio system will be featured at CIE's 4th Annual Orlando Live EUS symposium, which will be held September 7-9, 2016. 228 delegates from 20 countries attended the event in 2015.[1]

Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies, said, "There is a significant opportunity to improve the management of patients who suffer from pancreatic lesions when adding needle-based endomicroscopy to endoscopic ultra-sound, thereby reducing the need for potentially risky repeat procedures or even surgeries. This placement and relationship with the CIE team will increase Cellvizio awareness through their educational and research programs, while also allowing us to benefit from their learnings with the technology. We're excited to partner with the team at CIE to take this technology to the next level given their unique expertise and unrivalled recruitment of patients."

About the Florida Center for Interventional Endoscopy 

The Center for Interventional Endoscopy (CIE) was created to effectively integrate therapeutic endoscopy with minimally invasive surgery to provide state-of-the-art care for patients with complex digestive disease problems. Our mission is to foster cutting-edge clinical research and train the next generation of endoscopists and minimally invasive surgeons. The Center for Interventional Endoscopy (CIE) serves as a regional, national and international referral center for patients who may benefit from advanced endoscopic interventions. The center is staffed by a team of internationally renowned endoscopists who have extensive experience in the management of complex digestive disorders.

About Mauna Kea Technologies 

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.

For more information on Mauna Kea Technologies, visit http://www.maunakeatech.com

[1]  Florida Hospital Center for Interventional Endoscopy 2015 Annual Report

Mauna Kea Technologies
Benoit Jacheet
CFO
investors@maunakeatech.com    

United States
Zack Kubow / Lee Roth
The Ruth Group
+1-646-536-7020 / 7012
zkubow@theruthgroup.com / lroth@theruthgroup.com    

U.S. Media
Christopher Hippolyte
The Ruth Group
+1-646-536-7023
chippolyte@theruthgroup.com    

France and Europe
NewCap - Investor Relations
Florent Alba
+33(0)1-44-71-94-94
maunakea@newcap.fr


SOURCE Mauna Kea Technologies

PR Newswire
www.prnewswire.com

Last updated on: 31/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.